Boc-L-Tyrosine methyl ester:Exports & Compliance White Paper 2026

I. Executive Summary

Boc-L-tyrosine methyl ester (CAS 4326-36-7, C15H21NO5, Mr 295.34) is methyl N-tert-butoxycarbonyl-L-tyrosinate, an orthogonally protected amino-acid building block in which the amino group is masked as a tert-butoxycarbonyl carbamate, the carboxyl group is masked as a methyl ester, and the phenolic hydroxyl of the tyrosine side chain is deliberately left free. It is a white to off-white crystalline solid, readily soluble in methanol, ethyl acetate, dichloromethane, tetrahydrofuran and dimethylformamide and only sparingly soluble in water and alkane solvents. The material is supplied exclusively as a synthetic intermediate for peptide and peptidomimetic chemistry, not as a consumer product and not for human or veterinary administration. Commercial grades are typically specified at not less than 98 percent chromatographic purity with solvent and water limits appropriate to their intended use, and higher-specification lots are available where a customer needs them.

Its commercial importance has grown with the industrial build-out of peptide manufacturing. Large-scale solid-phase synthesis remains the default route for long sequences, but the economics of very large campaigns increasingly favour hybrid approaches in which short protected fragments made by solution-phase chemistry are condensed on resin or in solution. That shift favours exactly this class of molecule: partly protected, crystallisable, straightforwardly analysed and cheap enough to use in stoichiometric fragment coupling.

Three quality questions decide whether a supplier is credible. The first is chiral integrity, because base-mediated racemisation during esterification or protection produces the mirror-image enantiomer that later appears as a diastereomeric peptide impurity. The second is the fate of the unprotected phenol, which is simultaneously the reason the molecule is useful and the source of O-alkylation, O-acylation and tert-butylation side reactions. The third is whether the accompanying documentation matches the intended campaign grade, since research-use-only material and quality-agreement GMP material are different products wearing the same name.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The value of this building block lies in orthogonal protection. The methyl ester is stable to the coupling conditions and to acid treatments used for tert-butyl side-chain protection, but is cleanly cleaved by saponification or enzymatic hydrolysis when a free C-terminus is needed for fragment elongation. The tert-butoxycarbonyl group is stable to base and to catalytic hydrogenolysis, but is removed by trifluoroacetic acid or hydrogen chloride in an organic solvent. Because neither deprotection touches the phenolic oxygen, that oxygen remains available for later derivatisation.

• The Free Phenol as Handle and Liability: The unmasked phenolic hydroxyl permits late-stage sulfation to tyrosine-O-sulfate, phosphorylation, glycosylation or O-alkylation, enabling modified residues that would otherwise require a bespoke protected amino acid. The same nucleophilicity, however, allows O-acylation during activated-ester couplings and O-tert-butylation when tert-butyl cations are generated during acidolytic deprotection, so reports from experienced producers quantify those specific side products rather than reporting only total impurities.
• Chromophore-Enabled Analytics: Unlike aliphatic amino-acid derivatives, the phenolic ring gives strong ultraviolet absorbance near 275 nanometres, so assay and related-substance profiling can be run by conventional reversed-phase high-performance liquid chromatography with ultraviolet detection instead of evaporative light-scattering or charged-aerosol detection, which materially simplifies method transfer between supplier and customer laboratories.

2.2 Synthesis and Manufacturing Technologies

Two orders of operations define production, and the choice between them is decided by how well the supplier can suppress both racemisation and O-protection. Both begin with L-tyrosine of defined enantiomeric quality, since the stereocentre is inherited and is never created in the sequence.

• Esterification First, Then Carbamoylation: Tyrosine is converted to its methyl ester hydrochloride with methanol and an activating chloride reagent, the amine is liberated with base, and di-tert-butyl dicarbonate is introduced under aqueous-organic Schotten-Baumann-type conditions at controlled temperature and pH. This sequence avoids strong-base contact with the already-protected ester but demands rigorous control of di-Boc formation at the phenol and of residual chloride from the salt stage.
• Protection First, Then Gentle Esterification: The alternative protects tyrosine first and introduces the methyl ester afterwards using mild alkylating carbonate or carbodiimide-activation chemistry, or an immobilised lipase in an enzymatic route. It avoids chloride salt handling and can run at lower temperature, but it exposes the protected intermediate to nucleophilic catalysts that promote both racemisation and phenolic side reactions, and it typically requires chromatographic cleanup rather than crystallisation.

2.3 Core Application Matrix

• Solution-Phase and Hybrid Peptide Synthesis: Used as the N-terminally protected building block for dipeptide and tripeptide fragments that are later coupled in solution or condensed onto a resin-bound chain, exploiting clean saponification of the methyl ester to expose the next coupling position.
• Modified Tyrosine Residues and Diagnostic Peptides: Serves as the entry point for sulfated, phosphorylated and O-alkylated tyrosine analogues incorporated into peptide intermediates for enzyme substrates, diagnostic peptide constructs and reference standards prepared under research or GMP conditions.
• Chiral Synthon Beyond Peptides: The protected scaffold supports modification of the aromatic ring and reduction to cyclohexylalanine-type derivatives, making it a practical starting material for peptidomimetic and small-molecule synthesis programmes that need a defined stereocentre and a differentiated phenolic handle.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

The single dominant demand driver is the industrialisation of peptide therapeutic manufacturing. Successive approvals and rapid capacity expansion in incretin-class peptides have pulled forward demand for resins, coupling reagents and every category of protected amino acid, and have simultaneously pushed customers to reconsider pure solid-phase routes because solvent use and resin cost become punishing at multi-hundred-kilogram scale. Hybrid solution-phase strategies depend directly on crystallisable, analytically simple protected fragments of this type, and that dependence is visible in purchasing patterns, since customers qualifying a fragment-based route place multi-kilogram standing orders rather than occasional gram purchases.

3.2 Capacity Distribution and Export Flows

China supplies the great majority of peptide-reagent volume, with Shanghai, Zhejiang, Jiangsu and Shandong hosting manufacturers that grew from catalogue reagent businesses into campaign suppliers with kilogram-to-hundred-kilogram capability and, increasingly, separate GMP suites. European production clusters around Swiss, German and French peptide specialists together, with Italian fine-chemical CDMOs serving sponsors that require European audits and short technology transfer lead times. Japan retains a distinct position in very high-purity catalogued reference and research reagents sold in small quantities at premium prices.

3.3 Market Bifurcation and Pricing Dynamics

The price gap between a research-use-only catalogue gram and a quality-agreement GMP kilogram of the same CAS number can exceed an order of magnitude, and it is justified: the latter carries validated analytical methods, reference-standard management, cleaning validation, solvent-recovery qualification, change control and audit time. Buyers should treat those deliverables as the purchased item and the powder as incidental, the same way the earlier tier-question applies to any regulated building block.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Because this material is a building block rather than a registered substance with its own monograph, its regulatory status is assembled from three sources: chemical inventory and chemical-control law in each country through which it moves, the quality and supplier-qualification system of whoever buys it, and the dossier obligations of the eventual peptide applicant. A supplier that understands only the first of these will fail audit. In practice, the three intersect hardest at the impurity profile: a related substance that is entirely acceptable to a research customer may be unacceptable downstream because it is not purged and therefore has to be justified at the peptide stage.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH Registration and CLP Position: EU importers must establish that their tonnage is covered by an active registration held by the manufacturer, by an Only Representative, or by the manufacturer's own EU entity, because lower-volume amino-acid derivatives are frequently registered only by one or two lead registrants whose letters of access are priced accordingly. The delivered hazard profile should normally support an unclassified or minimally classified label, so any supplier proposing severe classifications is usually signalling impurity rather than identity.
• ICH Framework Applied by Peptide Sponsors: European customers building GMP peptides expect ICH Q7 working practice for campaign material, ICH Q11 reasoning including starting-material designation and purge arguments, an ICH Q3D elemental-impurity risk assessment and ICH Q3C residual-solvent classification, even where the formal obligation sits with the active substance manufacturer.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA Inventory and Import Documentation: Importers should hold a positive TSCA Inventory statement from the specific foreign manufacturer, since inventory listings are tied to the identity and sometimes to the reporting status of the producer, and generic assurances do not survive a customs query.
• Supporting FDA-Facing Campaigns: Sponsors submitting or holding peptide applications require supplier packages that include TSE and BSE statements, residual-solvent justification for methanol, dichloromethane and tetrahydrofuran against their permitted daily exposures, and documented change control so that a solvent switch cannot silently invalidate previously filed impurity data.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Amino-acid protection chemistry is a solvent- and salt-intensive business, and European buyers increasingly screen suppliers on that basis before discussing price. The most persuasive answers come from measurable process design rather than from certificates.

5.1 Carbon Footprint and Circular Economy

Process mass intensity is driven by extraction volumes, by isolation through chromatographic rather than crystallisation routes, and by campaign changeover cleaning in multipurpose plants. Suppliers who convert to crystallisation-based isolation, recover methanol and ethyl acetate on site, and can report cradle-to-gate figures with defined Scope 1 and Scope 2 boundaries are measurably ahead, and since peptide campaigns consume building blocks stoichiometrically, even modest per-kilogram improvements compound visibly at the customer's own product footprint. The same logic applies to waste: replacing halogenated extraction solvents removes a disposal liability that European customers now price explicitly into their total-cost comparisons.

5.2 Sustainable Sourcing and Traceability

Traceability expectations centre on origin of the L-tyrosine feedstock, absence of animal-derived processing aids where a customer requires that, and documented end-use screening. Because some peptide sequences fall within sport anti-doping prohibitions and certain peptide analogues attract misuse concerns, reputable suppliers of peptide building blocks apply know-your-customer procedures, require end-use declarations for bulk quantities, and decline orders that cannot be reconciled with legitimate research or registered manufacturing activity.

VI. Supply Chain Resilience and Export Logistics

The material is a stable crystalline solid that is normally not dangerous for transport, so logistics failures here are quality failures rather than safety incidents. Heat and humidity during transit hydrolyse the methyl ester and mobilise the tert-butoxycarbonyl group, and both effects show up as specifications failures on arrival rather than as visible damage.

6.1 Packaging Standards and Moisture/Contamination Control

• Barrier Packaging with Desiccant: Standard supply is a double polyethylene bag with desiccant inside a fibre drum, or amber glass bottles for small quantities, sealed to keep water content low so that neither the ester nor the carbamate can hydrolyse in transit.
• Defined Retest Under Cold, Dry Storage: Long-term storage is typically recommended at 2 to 8 degrees Celsius in a dry, well-closed container, with a retest period supported by stability data rather than an indefinite shelf-life claim, and with lots destined for GMP campaigns released only after confirmatory water and related-substance testing.

6.2 Dangerous Goods Identification and Transit Protocols

Shipments generally move as non-regulated goods under IMDG, ADR, RID and IATA, but that status must be confirmed per lot against its own classification data and residual solvent content. Because the specification is temperature sensitive, higher-value campaign lots travel by air with qualified insulated packaging and continuous temperature recording, and the temperature record itself becomes part of the receiving documentation, since an unrecorded excursion cannot be reconciled with a stability-backed retest period. Where sea freight is unavoidable for economy, buyers should specify desiccant quantity, container position away from heat sources, and a defined re-test on arrival rather than assuming that a non-dangerous-goods label implies ambient robustness.

VII. Enterprise Global Expansion Strategy Guide

Suppliers aiming to move from catalogue reagent to campaign partner should concentrate on three capabilities that customers cannot substitute with price competition elsewhere.

1. Own the Chiral Argument: Install and validate a chiral method, publish the enantiomeric impurity limit, and demonstrate through forced-degradation work where racemisation occurs, then remove that cause from the process rather than relying on purification.
2. Separate the Tiers Honestly: Run research-use-only and quality-agreement GMP campaigns in clearly distinguished production streams with different labelling, documentation and change control, so that the audit story for a regulated lot is never compromised by catalogue shortcuts.
3. Sell the Fragment, Not Just the Ester: Offer custom synthesis of short protected peptide fragments built from this building block, capturing the higher-value step while giving customers a directly usable input for their own hybrid synthesis route.

VIII. Conclusion

Boc-L-tyrosine methyl ester sits at an unusually favourable intersection: a genuinely simple, low-cost molecule that is nonetheless structurally enabling because of its free phenol and orthogonal protecting groups. As peptide manufacturing scales and hybrid synthesis strategies gain ground, demand for well-specified, crystallisable protected fragments will continue to expand, and the suppliers that benefit will be those who can evidence chiral control, phenolic side-reaction control and solvent compliance rather than those who simply quote the lowest price.

No therapeutic, efficacy or dosing claim is made for this product. It is supplied strictly as a synthetic building block for peptide and peptidomimetic chemistry, labelled Research Use Only where it is not manufactured under an applicable good manufacturing practice quality agreement, and it is not intended for human or veterinary administration or for use in any finished consumer product.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Boc-L-tyrosine methyl ester Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Boc-L-tyrosine methyl ester supply chain:

• Greater China Peptide Reagent Base: Shanghai, Zhejiang, Jiangsu and Shandong manufacturers that have scaled from catalogue reagents to kilogram and hundred-kilogram campaigns, some now operating dedicated GMP suites and validated chiral methods, supplying most global protected-amino-acid volume.
• European Peptide Specialists and CDMOs: Swiss, German, French and Italian producers combining peptide-specific process expertise with audit-ready quality systems, short technology-transfer cycles and the residual-solvent and elemental-impurity documentation European sponsors require.
• Japan High-Purity Reagent Houses: Established catalogued research-reagent suppliers known for tight specifications, small-quantity packaging and reliable analytical documentation, complementing larger-volume producers in India and the United States that serve industrial campaigns.